Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies - CytoMed Therapeutics (NASDAQ:GDTC)
SINGAPORE, July 21, 2025 ( GLOBE NEWSWIRE ) -- Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited GDTC ( "CytoMed" or "Company" ) , a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to ...
How this was made

The 30-second read
Why it matters
Successful trial progression may enhance company valuation and investor confidence.
Market read
The news is relevant primarily to biotech investors and stakeholders interested in cancer treatment developments.
What to watch
Regulatory hurdles, funding requirements, and competitive landscape could influence outcome.
Background
CytoMed Therapeutics is a Singapore-based biotech company focusing on cancer treatments.
Ticker impact
Primary focus due to recent clinical trial milestone.
Minimal immediate impact; potential long-term positive if trial progresses successfully.
The news confirms progress in clinical trials, which is positive but does not directly influence stock price until further milestones are achieved.
Market effects
Potential positive sentiment for biotech and clinical-stage pharmaceutical sectors.
Limited to Singapore and biotech-focused markets.
Moderate; reflects ongoing advancements in cancer therapeutics.
Counterpoint
Progress in clinical trials does not guarantee eventual market approval or commercial success.
Key entities
- CompanyCytoMed Therapeutics Limited
A clinical-stage biopharmaceutical company specializing in cancer therapeutics.
- Clinical TrialANGELICA Trial
A Phase 1 trial evaluating CytoMed's novel therapeutic approach.





